alexa Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.


Journal of Leukemia

Author(s): Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S

Abstract Share this page

Abstract We characterized the mutational status of the FLT3 tyrosine kinase domain (FLT3-TLD) in 3082 patients with newly diagnosed AML. FLT3-TKD mutations were detected in 147 of 3082 (4.8\%) patients. Similar to the FLT3 juxtamembrane domain mutations (FLT3-LM), there was a high correlation of FLT3-TKD mutations with normal karyotype (88 of 1472; 6.0\%). FLT3-TKD mutations were most frequent in the AML FAB subtypes M5b (15 of 114; 13.2\%), M3v (6 of 51; 11.8\%), and M4 (39 of 484; 8.1\%). Similar to FLT3-LM, the FLT3-TKD mutations show elevated peripheral leukocytes compared with FLT3wt AML. FLT3-TKD had a high incidence in cases with NPM1 mutations (23 of 262; 8.8\%), CEBPA mutations (6 of 76; 7.9\%), and NRAS mutations (6 of 78; 7.7\%). FLT3-TKD in combination with FLT3-LM (17 of 594 patients; 2.9\%) and KITD816 (1 of 44; 2.3\%) was rare. Unlike the FLT3-LM, which are associated with inferior survival, prognosis was not influenced by FLT3-TKD in the total cohort of 1720 cases, where follow-up data were available (97 FLT3-TKD; 1623 FLT3-WT). In t(15;17)/PML-RARA with FLT3-TKD mutations, in FLT3-LM/TKD double-mutated, and in MLL-PTD/TKD double-mutated cases prognosis was unfavorably influenced by FLT3-TKD mutations. In contrast, we found an additional favorable impact of FLT3-TKD on EFS in prognostically favorable AML with NPM1- or CEBPA mutations. This article was published in Blood and referenced in Journal of Leukemia

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version